Xeris Pharmaceuticals | XERS - Operating Expenses

Stock Price
6.04
Daily Change
0 0%
Monthly
7.86%
Yearly
36.96%
Q2 Forecast
5.86

Xeris Pharmaceuticals reported $69.03M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Celltrion KRW 724.99B 6B Sep/2025
Cspc Pharmaceutical CNY 5.91B 512.77M Dec/2025
Deva Holding AS TRY 1.35B 178.26M Sep/2023
Dianthus Therapeutics USD 69.82M 29.14M Dec/2025
Divis Laboratories Ltd INR 18.32B 1.08B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Kangmei Pharma CNY 1.39B 144.29M Sep/2025
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 21.61M 11.59M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neuren Pharmaceuticals AUD 25.23M 16.54M Dec/2025
Organigram Holdings CAD 83.66M 24.44M Dec/2025
Ovoca Bio EUR 1.16M 4.48M Jun/2025
Pacira USD 193.68M 27.32M Dec/2025
Perrigo USD 1.03B 75.3M Dec/2025
Pharma Mar EUR 46.87M 7.24M Dec/2025
Qiagen NV USD 418.54M 23.25M Dec/2025
Sartorius EUR 693.1M 29.4M Sep/2025
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
Supernus Pharmaceuticals USD 197.75M 54.54M Dec/2025
Tilray USD 237.52M 17.34M Sep/2025
Zealand Pharma A/S 775.97M 265.08M Dec/2025
Zz Pientze Pharmaceu CNY 1.55B 129.66M Sep/2025